EntreMed (ENMD) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mark Wise who wrote ()	3/25/1999 5:43:00 AM
From: Tommy Johnsen	Read Replies (1) of 2135

Have any of you Entremed-holders (or shorters) taken a look at OXiGENE (OXGN) lately ? Their vascular-targeting agent Combretastatin, is now in phase 1/2 trials in the US/England (as opposed to enmd's preclinical),and so far it seems to going extremely well. Rumour has it that one patient has actually recovered totally, and that phase 3 trials could be reached as soon as september/november. If this is true, oxgn could easily be a 60-dollar stock this fall! OXiGENE's management are presently involved in disussions with several big players (including BMY...), and a deal could come at any time. News from the Combretastatin-study should also be out before summer. In my understanding, with the info I've got, this stock is outragously undervalued. I'd appreciate any comments from others !

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next